floxuridine and Cancer of Liver studies

Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.

Research Excerpts

Excerpt	Relevance	Reference
"To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer."	9.19	Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014)
"The aim of this study was to evaluate the therapeutic efficacy and safety of hepatic arterial infusion (HAI) with irinotecan, oxaliplatin, and floxuridine as a firstline treatment in patients with unresectable liver metastases of colorectal cancer (CRC)."	9.16	Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer. ( Chen, Y; Liu, Q; Luo, J; Wang, J; Wang, X; Yan, Z, 2012)
"To evaluate the therapeutic efficacy and safety of combination chemotherapy with oxaliplatin, irinotecan and doxifluridine through hepatic arterial infusion (HAI) in patients with unresectable liver metastases of colorectal cancer."	9.14	Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer. ( Chen, Y; Liu, Q; Luo, J; Wang, J; Wang, X; Yan, Z, 2010)
"Irinotecan (CPT-11) and doxifluridine (5'-DFUR) are active agents against colorectal cancer."	9.11	Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer. ( Fujimoto-Ouchi, K; Kato, T; Kikkawa, N; Mishima, H; Nishisho, I; Tanaka, Y; Tsujie, M; Tsujinaka, T; Yanagisawa, M, 2005)
"This study was designed to evaluate hepatic arterial infusion of floxuridine (FUDR) in patients with resected hepatic metastases from colorectal cancer."	9.09	Phase II evaluation of treatment of complete resection of hepatic metastases from colorectal cancer and adjuvant hepatic arterial infusion of floxuridine: an Eastern Cooperative Oncology Group Study (PB083). ( Berlin, J; Lerner, H; Merrick, HW; Smith, TJ, 1999)
"The effect of the combination treatment consisted of 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA) was investigated in 20 recurrent breast cancer patients."	9.08	[The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient]. ( Hayashi, K; Taniguchi, T; Toi, M; Tominaga, T, 1995)
"To conduct a pilot trial of hepatic arterial infusion (HAI) of floxuridine (FUDR), leucovorin, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (FLAP) in nonresectable hepatocellular cancer (HCC) confined to the liver and assess the effects of hepatitis B (HBV) and hepatitis C (HCV) viral markers on toxicity, response to treatment, and patient survival."	9.07	Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. ( Carrasco, H; Charnsangavej, C; Chase, J; Chuang, V; Fischer, H; Lawrence, D; Patt, YZ; Roh, M; Smith, R; Yoffe, B, 1994)
"We studied three new dose schedules of hepatic arterial infusion of floxuridine (FUDR) and leucovorin and update survival analysis of a previously reported trial using these drugs by hepatic arterial infusion for patients with hepatic metastases from colorectal carcinoma."	9.07	Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. ( Bertino, JR; Botet, J; Budd, AJ; Chapman, D; Cohen, A; Conti, JA; Kemeny, N; Mazumdar, M; Seiter, K; Sigurdson, ER, 1994)
"This study was designed to determine if hepatic arterial therapy with floxuridine (F), mitomycin, and carmustine (BCNU) (FMB) is superior to hepatic arterial therapy with F alone in previously treated patients with hepatic metastases from colorectal cancer."	9.07	Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. ( Botet, J; Budd, A; Cohen, A; Conti, JA; Kemeny, N; Niedzwiecki, D; Seiter, K; Sigurdson, ER; Tao, Y, 1993)
"Hepatic intra-arterial (HIA) infusion of floxuridine (FUDR) via an implanted pump has shown promise in the treatment of colorectal cancer metastasized to the liver."	9.07	Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. ( Chase, JL; Grobman, BJ; Hohn, DC; Lewis, BJ; Mulvihill, SJ; Rayner, AA; Roh, M; Stagg, RJ; Venook, AP; Warren, RS, 1991)
"Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection."	9.06	Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990)
"In 1983, the Northern California Oncology Group (NCOG) instituted a randomized trial of intravenous (IV) versus intraarterial (IA) floxuridine (FUDR) administered via an implantable pump for patients with colorectal cancer metastatic to the liver."	9.06	A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. ( Acord, P; Friedman, MA; Hannigan, JF; Hohn, DC; Ignoffo, RJ; Lewis, BJ; Rayner, A; Stagg, RJ, 1989)
"Salvage treatment with 5-fluorouracil (5-FU) with or without leucovorin may induce responses in patients with advanced colorectal cancer whose disease progresses after adjuvant therapy with the same drugs."	8.80	Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? ( Goldberg, RM, 1998)
"To evaluate and compare the efficiency and safety of raltitrexed- or floxuridine (FUDR)-based transarterial chemoembolization (TACE) in patients with unresectable colorectal cancer liver metastasis (CRCLM)."	7.91	Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis. ( He, XH; Huang, HZ; Li, GD; Li, WT; Wang, GZ; Wang, Y; Wang, YH; Wei, N; Xu, LC; Zhang, B, 2019)
"This study aimed to compare the efficacy and safety of HAI fluoropyrimidine (FUDR)/capecitabine or single capecitabine as first-line treatment for elderly patients with unresectable colorectal liver metastases (CLMs)."	7.83	First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastases. ( Ding, W; Ji, M; Jiang, J; Li, X; Lu, Q; Qiang, W; Shi, L; Wu, C; Wu, J; Zhao, J, 2016)
"We investigated whether the efficacy of peroral doxifluridine and hepatic arterial 5-FU infusion on synchronous liver metastasis of colorectal cancer could be predicted based on the expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in the primary colorectal lesions."	7.71	[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]. ( Fujioka, M; Hashimoto, D; Hoshino, T; Inokuma, S; Ishida, H; Ishizuka, N; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Takeuchi, I; Yamada, H; Yokoyama, M, 2001)
"The results support a role for p53 "hot spot" mutations in colorectal liver metastasis resistance to fluorinated pyrimidines, and suggest that the presence of such mutations may be a contra-indication to treatment of colorectal liver metastases with hepatic arterial floxuridine."	7.71	P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases. ( Allen-Mersh, TG; Feldmann, KA; Ivison, A; Jonas, SK; Khan, ZA; Patel, H; Tarragona, A; Wharton, RQ, 2001)
"A 60-year-old woman with her right breast cancer showing simultaneous and multiple liver metastases was initially treated with CEFT [cyclophosphamide (CPA), epirubicin (epi-ADM), 5-fluorouracil (5-FU), tamoxifen (TAM)]."	7.70	[A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)]. ( Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M, 1999)
"An advanced breast cancer patient refractory to CAF (Cyclophosphamide, Adriamycin, 5-fluorouracil), 5-FU-Methotrexate sequential therapy and Tamoxifen was treated with the combination 5' DFUR, MMC, Etoposide and MPA."	7.68	[5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer]. ( Ohtagaki, S; Toge, T; Toi, M; Yagi, M; Yoshinaka, K, 1991)
"We report the clinical and radiologic findings and course of two patients who developed drug-related biliary sclerosis during hepatic artery infusion of floxuridine."	7.67	Biliary sclerosis associated with hepatic artery infusion of floxuridine. ( Bolton, JS; Bowen, JC, 1986)
"To evaluate clinical outcomes when HAI chemotherapy is combined with systemic chemotherapy in patients with unresectable IHC."	6.94	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. ( Allen, PJ; Balachandran, VP; Boerner, T; Boucher, TM; Cercek, A; Chapman, WC; Chou, JF; D'Angelica, MI; DeMatteo, RP; Diaz, LA; Do, RKG; Drebin, JA; Fields, RC; Gönen, M; Harding, JJ; Hauser, HF; Hawkins, WG; Jarnagin, WR; Kemeny, NE; Kingham, TP; Lim, KH; Lowery, MA; Majella Doyle, MB; Reidy-Lagunes, D; Saltz, L; Sanchez-Vega, F; Schultz, N; Strasberg, SM; Tan, BR; Vachharajani, N; Varghese, AM, 2020)
"Only patients with colorectal cancer who had evidence of unresectable metastases confined to the liver were eligible."	6.69	Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. ( Bernath, AM; Bolton, JS; Burch, P; Colon-Otero, G; Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Nagorney, DM; O'Connell, MJ; Schroeder, G, 1998)
"All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)."	6.69	Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999)
"Doxifluridine is an oral fluoropyrimidine derivative activated to 5-fluorouracil by uridine phosphorylase which is more expressed in malignant cells."	6.69	Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study. ( Allegrini, G; Bartolozzi, C; Brunetti, I; Conte, PF; Di Marsico, R; Falcone, A; Fontana, E; Lencioni, M; Masi, G; Orlandini, C; Pfanner, E; Stampino, CG, 2000)
"Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues."	6.68	Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997)
"Although most patients with gestational trophoblastic neoplasia (GTN) are cured by conventional chemotherapy, some develop drug resistance or relapse."	5.37	Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. ( Feng, F; Geng, S; Wan, X; Wang, T; Xiang, Y, 2011)
"Thirty-nine patients with hepatocellular carcinoma were treated with oral 5'-DFUR for more than 4 d before operation."	5.33	5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma. ( Wang, HD; Zheng, JF, 2005)
"To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer."	5.19	Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014)
"The aim of this study was to evaluate the therapeutic efficacy and safety of hepatic arterial infusion (HAI) with irinotecan, oxaliplatin, and floxuridine as a firstline treatment in patients with unresectable liver metastases of colorectal cancer (CRC)."	5.16	Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer. ( Chen, Y; Liu, Q; Luo, J; Wang, J; Wang, X; Yan, Z, 2012)
"This study utilized the imaging data of primary liver cancer (PLC) treated with floxuridine (FUDR) and bevacizumab to test the hypothesis that dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters correlate with tissue hypoxia markers and treatment outcome."	5.15	Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. ( Allen, PJ; Bamboat, Z; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; Gultekin, DH; Haviland, D; Jarnagin, WR; Kemeny, N; Schwartz, LH; Shia, J; Yopp, AC, 2011)
"This study reports the results of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (dex) in patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) and investigates dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) assessment of tumor vascularity as a biomarker of outcome."	5.14	Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. ( Blumgart, LH; D'Angelica, M; DeMatteo, R; Fong, Y; Gönen, M; Gultekin, DH; Haviland, D; Jarnagin, WR; Kemeny, N; Schwartz, LH; Shia, J; Tse, A, 2009)
" Oxaliplatin combined with capecitabine has demonstrated activity in advanced colorectal cancer."	5.14	Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI- ( Alberts, SR; Bolton, JS; Dentchev, T; Lai, LL; Mahoney, MR; Molina, R; Nagorney, DM; O'Connell, MJ; Roh, MS; Schwarz, RE; Smyrk, TC; Wagman, L; Weiland, TL, 2010)
"To evaluate the therapeutic efficacy and safety of combination chemotherapy with oxaliplatin, irinotecan and doxifluridine through hepatic arterial infusion (HAI) in patients with unresectable liver metastases of colorectal cancer."	5.14	Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer. ( Chen, Y; Liu, Q; Luo, J; Wang, J; Wang, X; Yan, Z, 2010)
"Irinotecan (CPT-11) and doxifluridine (5'-DFUR) are active agents against colorectal cancer."	5.11	Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer. ( Fujimoto-Ouchi, K; Kato, T; Kikkawa, N; Mishima, H; Nishisho, I; Tanaka, Y; Tsujie, M; Tsujinaka, T; Yanagisawa, M, 2005)
"The results suggest that, compared with historical controls, high-dose focal liver irradiation with hepatic artery floxuridine prolongs survival in patients with unresectable chemotherapy-refractory metastatic colorectal cancer and primary hepatobiliary tumors."	5.11	Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. ( Ben-Josef, E; Dawson, LA; Ensminger, WD; Knol, J; Lawrence, TS; Normolle, D; Pan, C; Tatro, D; Ten Haken, RK; Walker, S, 2005)
"This study was designed to evaluate hepatic arterial infusion of floxuridine (FUDR) in patients with resected hepatic metastases from colorectal cancer."	5.09	Phase II evaluation of treatment of complete resection of hepatic metastases from colorectal cancer and adjuvant hepatic arterial infusion of floxuridine: an Eastern Cooperative Oncology Group Study (PB083). ( Berlin, J; Lerner, H; Merrick, HW; Smith, TJ, 1999)
"We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alone."	5.09	Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. ( Bertino, JR; Blumgart, LH; Brennan, MF; Cohen, AM; Conti, JA; Fong, Y; Huang, Y; Kemeny, N; Shi, W; Stockman, J; Sullivan, D; Turnbull, AD, 1999)
"The effect of the combination treatment consisted of 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA) was investigated in 20 recurrent breast cancer patients."	5.08	[The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient]. ( Hayashi, K; Taniguchi, T; Toi, M; Tominaga, T, 1995)
"To conduct a pilot trial of hepatic arterial infusion (HAI) of floxuridine (FUDR), leucovorin, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (FLAP) in nonresectable hepatocellular cancer (HCC) confined to the liver and assess the effects of hepatitis B (HBV) and hepatitis C (HCV) viral markers on toxicity, response to treatment, and patient survival."	5.07	Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. ( Carrasco, H; Charnsangavej, C; Chase, J; Chuang, V; Fischer, H; Lawrence, D; Patt, YZ; Roh, M; Smith, R; Yoffe, B, 1994)
"We studied three new dose schedules of hepatic arterial infusion of floxuridine (FUDR) and leucovorin and update survival analysis of a previously reported trial using these drugs by hepatic arterial infusion for patients with hepatic metastases from colorectal carcinoma."	5.07	Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. ( Bertino, JR; Botet, J; Budd, AJ; Chapman, D; Cohen, A; Conti, JA; Kemeny, N; Mazumdar, M; Seiter, K; Sigurdson, ER, 1994)
"This study was designed to determine if hepatic arterial therapy with floxuridine (F), mitomycin, and carmustine (BCNU) (FMB) is superior to hepatic arterial therapy with F alone in previously treated patients with hepatic metastases from colorectal cancer."	5.07	Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. ( Botet, J; Budd, A; Cohen, A; Conti, JA; Kemeny, N; Niedzwiecki, D; Seiter, K; Sigurdson, ER; Tao, Y, 1993)
"Hepatic intra-arterial (HIA) infusion of floxuridine (FUDR) via an implanted pump has shown promise in the treatment of colorectal cancer metastasized to the liver."	5.07	Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. ( Chase, JL; Grobman, BJ; Hohn, DC; Lewis, BJ; Mulvihill, SJ; Rayner, AA; Roh, M; Stagg, RJ; Venook, AP; Warren, RS, 1991)
"Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection."	5.06	Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990)
"In 1983, the Northern California Oncology Group (NCOG) instituted a randomized trial of intravenous (IV) versus intraarterial (IA) floxuridine (FUDR) administered via an implantable pump for patients with colorectal cancer metastatic to the liver."	5.06	A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. ( Acord, P; Friedman, MA; Hannigan, JF; Hohn, DC; Ignoffo, RJ; Lewis, BJ; Rayner, A; Stagg, RJ, 1989)
"Salvage treatment with 5-fluorouracil (5-FU) with or without leucovorin may induce responses in patients with advanced colorectal cancer whose disease progresses after adjuvant therapy with the same drugs."	4.80	Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? ( Goldberg, RM, 1998)
"To evaluate the benefits and risks of hepatic artery infusion (HAI) gemcitabine and floxuridine (FUDR) in patients with nasopharyngeal carcinoma liver metastases."	3.96	Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis. ( Li, G; Li, H; Peng, C; Shi, L; Zhou, C, 2020)
"To evaluate and compare the efficiency and safety of raltitrexed- or floxuridine (FUDR)-based transarterial chemoembolization (TACE) in patients with unresectable colorectal cancer liver metastasis (CRCLM)."	3.91	Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis. ( He, XH; Huang, HZ; Li, GD; Li, WT; Wang, GZ; Wang, Y; Wang, YH; Wei, N; Xu, LC; Zhang, B, 2019)
"This study aimed to compare the efficacy and safety of HAI fluoropyrimidine (FUDR)/capecitabine or single capecitabine as first-line treatment for elderly patients with unresectable colorectal liver metastases (CLMs)."	3.83	First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastases. ( Ding, W; Ji, M; Jiang, J; Li, X; Lu, Q; Qiang, W; Shi, L; Wu, C; Wu, J; Zhao, J, 2016)
"To investigate the efficacy of hepatic arterial infusion chemotherapy (HAIC) using floxuridine (FUDR) in patients with advanced hepatocellular carcinoma (HCC) confined to the liver."	3.78	Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. ( Baek, YH; Cho, JH; Choi, YM; Han, SY; Jeong, JS; Kim, KT; Kim, YH; Lee, HS; Lee, SW; Nam, KJ; Park, BH; Roh, YH, 2012)
"PURPOSE To determine the conversion to resectability in patients with unresectable liver metastases from colorectal cancer treated with hepatic arterial infusion (HAI) plus systemic oxaliplatin and irinotecan (CPT-11)."	3.75	Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. ( Capanu, M; D'Angelica, M; Fong, Y; Jarnagin, WR; Kemeny, NE; Melendez, FD; Patel, D; Paty, PB; Schwartz, LH, 2009)
"High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer."	3.74	[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy]. ( Murakami, S; Yamamoto, Y, 2007)
" Our study population was patients who had undergone arterial mapping in preparation for placement of a hepatic arterial floxuridine infusion pump for treatment of metastatic hepatic colorectal carcinoma."	3.72	Multidetector CT arteriography with volumetric three-dimensional rendering to evaluate patients with metastatic colorectal disease for placement of a floxuridine infusion pump. ( Brancatelli, G; Federle, MP; Geller, DA; Kapoor, V; Katyal, S; Marsh, JW, 2003)
"Hepatic intra-arterial infusion chemotherapy of 5-fluorouracil (5-FU) or fluorodeoxyuridine (FUDR) has been a treatment option for liver metastasis from colorectal cancer."	3.72	Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model. ( Ishikawa, K; Makuuchi, H; Masuda, T; Murayama, C; Nakamura, T; Sadahiro, S; Suzuki, T; Tanaka, Y; Yasuda, S, 2003)
"In metastatic colorectal cancer the oral 5-fluorouracil (5FU) prodrug capecitabine is used with increasing frequency as an alternative to i."	3.72	In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. ( Heerschap, A; Kamm, YJ; Klomp, DW; Punt, CJ; van Laarhoven, HW, 2003)
"The present results suggest that coupling to lactosaminated albumin might improve the effect of floxuridine in adjuvant chemotherapy of colorectal cancer by exposing the cells of liver micrometastases (nourished by hepatic sinusoids) to enhanced drug concentrations."	3.71	Floxuridine coupling with lactosaminated human albumin to increase drug efficacy on liver micrometastases. ( Busi, C; Di Stefano, G; Fiume, L, 2002)
"We investigated whether the efficacy of peroral doxifluridine and hepatic arterial 5-FU infusion on synchronous liver metastasis of colorectal cancer could be predicted based on the expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in the primary colorectal lesions."	3.71	[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]. ( Fujioka, M; Hashimoto, D; Hoshino, T; Inokuma, S; Ishida, H; Ishizuka, N; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Takeuchi, I; Yamada, H; Yokoyama, M, 2001)
"The results support a role for p53 "hot spot" mutations in colorectal liver metastasis resistance to fluorinated pyrimidines, and suggest that the presence of such mutations may be a contra-indication to treatment of colorectal liver metastases with hepatic arterial floxuridine."	3.71	P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases. ( Allen-Mersh, TG; Feldmann, KA; Ivison, A; Jonas, SK; Khan, ZA; Patel, H; Tarragona, A; Wharton, RQ, 2001)
"A 60-year-old woman with her right breast cancer showing simultaneous and multiple liver metastases was initially treated with CEFT [cyclophosphamide (CPA), epirubicin (epi-ADM), 5-fluorouracil (5-FU), tamoxifen (TAM)]."	3.70	[A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)]. ( Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M, 1999)
"Twelve patients with liver metastases of breast cancer were treated with hepatic arterial infusion chemotherapy using 20-30 mg/body of epi-adriamycin (epi-ADM) every 2 weeks and continuous infusion of 250 mg/body/day of 5-fluorouracil (5-FU)."	3.69	[Intra-arterial infusion chemotherapy for liver metastases from breast cancer]. ( Furukawa, J; Kinuta, M; Maruhashi, S; Maruyama, H; Masuda, N; Matsui, S; Okamura, J; Ooi, H; Takiguchi, S; Tateishi, H; Tokunaga, M; Yano, H; Yayoi, E, 1996)
"An advanced breast cancer patient refractory to CAF (Cyclophosphamide, Adriamycin, 5-fluorouracil), 5-FU-Methotrexate sequential therapy and Tamoxifen was treated with the combination 5' DFUR, MMC, Etoposide and MPA."	3.68	[5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer]. ( Ohtagaki, S; Toge, T; Toi, M; Yagi, M; Yoshinaka, K, 1991)
" One patient had severe ileitis caused by intravenous administration of 5-fluorouracil; the other had severe duodenitis caused by infusion of 5-floxuridine into the hepatic artery by an implanted pump."	3.68	Gastrointestinal toxicity of 5-FU and 5-FUDR: radiographic findings. ( Hiehle, JF; Levine, MS, 1991)
"Based on laboratory studies showing enhanced cytotoxicity of floxuridine (FUDR) when used with high doses of leucovorin (LV), a pilot study of FUDR and LV through an implantable pump was initiated for the treatment of hepatic metastases from colorectal cancer."	3.68	Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma. ( Bertino, JR; Botet, J; Cohen, A; Kemeny, N; Oderman, P; Sigurdson, ER, 1990)
"We report the clinical and radiologic findings and course of two patients who developed drug-related biliary sclerosis during hepatic artery infusion of floxuridine."	3.67	Biliary sclerosis associated with hepatic artery infusion of floxuridine. ( Bolton, JS; Bowen, JC, 1986)
"The action of floxuridine depends greatly on its concentration for treatment of liver metastases of colorectal carcinomas and other tumors."	3.66	[Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors]. ( Balch, CM; Urist, MM, 1983)
"To evaluate clinical outcomes when HAI chemotherapy is combined with systemic chemotherapy in patients with unresectable IHC."	2.94	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. ( Allen, PJ; Balachandran, VP; Boerner, T; Boucher, TM; Cercek, A; Chapman, WC; Chou, JF; D'Angelica, MI; DeMatteo, RP; Diaz, LA; Do, RKG; Drebin, JA; Fields, RC; Gönen, M; Harding, JJ; Hauser, HF; Hawkins, WG; Jarnagin, WR; Kemeny, NE; Kingham, TP; Lim, KH; Lowery, MA; Majella Doyle, MB; Reidy-Lagunes, D; Saltz, L; Sanchez-Vega, F; Schultz, N; Strasberg, SM; Tan, BR; Vachharajani, N; Varghese, AM, 2020)
"Patients with unresectable intrahepatic cholangiocarcinoma (iCCA) have poor survival."	2.82	Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. ( de Jonge, J; de Wilde, RF; El Hassnaoui, M; Franssen, S; Groot Koerkamp, B; Holster, JJ; Homs, MYV; IJzermans, JNM; Mostert, B; Polak, WG, 2022)
"Patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) were treated with HAI FUDR/Dex plus IV Bev."	2.76	Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? ( Allen, P; D'Angelica, MI; Fong, Y; Gewirtz, AN; Gönen, M; Gultekin, D; Haviland, D; Jarnagin, WR; Kemeny, NE; Schwartz, L; Yopp, A, 2011)
"Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to receive preoperative hepatic and regional arterial chemotherapy (PHRAC group, n = 110) or surgery alone (control group, n = 112)."	2.73	Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. ( Jianhua, W; Jiemin, C; Li, R; Weixin, N; Xinyu, Q; Xu, J; Yanhan, L; Zhiping, Y; Zhong, Y, 2007)
" The purpose of the present study was to examine the efficacy of long-term administration of 5'-DFUR/CPA for patients with recurrent breast cancer."	2.71	The efficacy of long-term oral chemotherapy with 5'-deoxy-5-fluorouridine and cyclophosphamide for recurrent breast cancer. ( Aihara, N; Fukunaga, M; Iba, T; Kidokoro, A; Suda, M; Sugiyama, K, 2004)
"Most colorectal cancers metastatic to the liver are resistant to chemotherapy and are not amenable to surgical resection."	2.70	Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. ( Bilchik, AJ; Chawla, SP; Chung, MH; Foshag, LJ; Ramming, KP; Rose, DM; Stern, SS; Wood, TF, 2001)
"Unresectable colorectal liver metastases are a significant clinical problem."	2.70	Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. ( Alexander, HR; Bartlett, DL; Figg, WD; Fraker, DL; Libutti, SK, 2001)
"47%, P = 0."	2.70	Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. ( Anderson, J; Burton, M; Gebski, V; Gray, B; Hope, M; Moroz, P; Van Hazel, G, 2001)
"Patients with one to three potentially resectable metastases were randomized preoperatively to receive no further therapy (control arm, 56 patients) or postoperative hepatic arterial floxuridine combined with intravenous continuous-infusion fluorouracil (chemotherapy arm, 53 patients)."	2.70	Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. ( Adak, S; Benson, AB; Gray, B; Kemeny, MM; Lipsitz, S; Macdonald, JS; O'Dwyer, PJ; Sigurdson, ER; Smith, T, 2002)
"Only patients with colorectal cancer who had evidence of unresectable metastases confined to the liver were eligible."	2.69	Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. ( Bernath, AM; Bolton, JS; Burch, P; Colon-Otero, G; Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Nagorney, DM; O'Connell, MJ; Schroeder, G, 1998)
"All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)."	2.69	Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999)
"Median times to disease progression for the three treatment arms were as follows: 9."	2.69	Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore ( Lorenz, M; Müller, HH, 2000)
"Doxifluridine is an oral fluoropyrimidine derivative activated to 5-fluorouracil by uridine phosphorylase which is more expressed in malignant cells."	2.69	Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study. ( Allegrini, G; Bartolozzi, C; Brunetti, I; Conte, PF; Di Marsico, R; Falcone, A; Fontana, E; Lencioni, M; Masi, G; Orlandini, C; Pfanner, E; Stampino, CG, 2000)
"Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues."	2.68	Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997)
" Combination with high-dose 5'-DFUR and low-dose intra-hepatic arterial infusion of CDDP is considered a very effective chemotherapy which can be performed ambulatorily while maintaining the quality of life of patients with liver metastases of gastric cancer."	2.67	[Combination with intra-hepatic arterial infusion of low-dose cisplatin and oral administration of high-dose doxyfluridine in patients with liver metastases of gastric cancer]. ( Kikkawa, N; Kobayashi, K; Mishima, H; Shin, E; Takatsuka, Y; Tamaki, Y; Tono, T; Yagyu, T, 1994)
"Gastritis was heralded in these patients by epigastric pain and tenderness, nausea, vomiting, weakness, and anorexia."	2.67	Gastric mucosal injury after hepatic arterial infusion chemotherapy with floxuridine. A clinical and pathologic study. ( Doria, LK; Doria, MI; Faintuch, J; Levin, B, 1994)
" The dosage was 0."	2.66	Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial. ( Beger, GH; Bittner, R; Gaus, W; Roscher, R; Safi, F; Schuhmacher, K, 1989)
"5'-DFUR was administered orally to advanced or recurrent cancer patients at a daily dosage of 600-1200 mg divided into 3 or 4 times a day."	2.66	[Clinical trial of 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced cancer patients]. ( Imamura, Y; Irie, K; Nakamura, T; Suehiro, I; Yasutake, K; Yoshida, M; Yoshimura, Y, 1985)
" Continuous floxuridine infusion was given at a dosage of 0."	2.66	Regional infusion for colorectal hepatic metastases. A randomized trial comparing the hepatic artery with the portal vein. ( Daly, JM; Kemeny, N; Oderman, P; Sigurdson, E; Thom, A, 1987)
"A PR of hepatic metastases was noted in eight patients (35%) with a median and mean duration of response of 4."	2.64	Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil. ( Buroker, T; Correa, J; Fraile, R; Samson, M; Vaitkevicius, VK, 1976)
"A form of non-alcoholic steatohepatitis (NASH) related to chemotherapy and otherwise known as chemotherapy-associated steatohepatitis (CASH) is closely linked to irinotecan-based therapy and is associated with inferior outcomes following hepatic surgery mainly due to hepatic insufficiency and poor regeneration."	2.45	Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. ( Khan, AZ; Makuuchi, M; Morris-Stiff, G, 2009)
"Floxuridine (FUDR) is an ideal drug for hepatic arterial infusion (HAI) due to its short half life, steep dose response curve, high total body clearance, and high hepatic extraction."	2.45	The role of floxuridine in metastatic liver disease. ( Kemeny, NE; Power, DG, 2009)
"Resectability of liver-limited colorectal cancer metastases should be considered as an endpoint for all patients."	2.44	Regional chemotherapy for liver-limited metastatic colorectal cancer. ( Healey-Bird, BR; Kemeny, NE; Power, DG, 2008)
"Colorectal cancer is a leading cause of cancer death world-wide."	2.42	Review article: colorectal cancer chemotherapy. ( Gill, S; Goldberg, RM; Thomas, RR, 2003)
"Patients with colorectal cancer commonly succumb to the sequelae of hepatic metastases."	2.42	Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. ( Barber, FD; Kurzrock, R; Mavligit, G, 2004)
"Progression of colorectal cancer can occur primarily isolated in the liver."	2.41	Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries. ( Gog, C; Heinrich, S; Lorenz, M; Müller, HH; Petrowsky, H; Staib-Sebler, E; Vetter, G, 2000)
"In advanced colorectal cancer, liver metastases are a major problem."	2.41	Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. ( Giaccone, G; Pinedo, HM; van Groeningen, CJ; van Riel, JM, 2000)
" Fluorodeoxyuridine (FUDR) or 5-fluorouracil (5-FU) was used as the agent and a total dosage of 10-20 g was administered for 6-12 months in most studies."	2.41	[The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer]. ( Monden, T; Tono, T, 2000)
"Approximately 20% of patients with colorectal cancer die of metastases confined to the liver."	2.40	Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. ( Allen-Mersh, TG; Buyse, M; Carlson, R; Chang, AE; Durand-Zaleski, I; Fagniez, PL; Kemeny, MM; Le Bourgeois, JP; O'Connell, MJ; Piedbois, P; Roche, B; Rougier, P; Sondak, VK, 1997)
"Fifty per cent of patients with colorectal cancer develop hepatic metastases but only a minority are candidates for potentially curative surgical resection."	2.39	Hepatic artery chemotherapy for colorectal liver metastases. ( Jorgensen, JO; McCall, JL; Morris, DL, 1995)
"Hepatic metastasis is usually quite resistant to conventional systemic chemotherapy."	2.36	Nonsystemic treatment of metastatic tumors of the liver--a review. ( Lee, YT, 1978)
"A floxuridine assay with a lower boundary of detection of 0."	1.91	Systemic exposure of floxuridine after hepatic arterial infusion pump chemotherapy with floxuridine in patients with resected colorectal liver metastases. ( Bruijn, P; Buisman, FE; Doorn, LV; Doornebosch, PG; Filipe, WF; Grootscholten, C; Grünhagen, DJ; Holster, JJ; Homs, MYV; IJzerman, NS; Koerkamp, BG; Kok, NFM; Koolen, SLW; Kuhlmann, KFD; Mathijssen, RHJ; van Bommel, CPE; Verhoef, C, 2023)
" Medical oncology experience in floxuridine dosing is critical in maximizing the treatment doses and the number of cycles administered while avoiding biliary toxicity."	1.91	Starting a successful hepatic artery infusion pump program: A practical guide. ( Barry-Hundeyin, M; Cavnar, MJ; Ellis, CS; Gholami, S; Kim, J; McDonald, HG; Pandalai, PK; Patel, RA, 2023)
"Resection of multifocal intrahepatic cholangiocarcinoma needs to be considered carefully given the complication rate of major liver resection; HAIP floxuridine chemotherapy may be an effective alternative option."	1.72	Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma. ( Aldrighetti, L; Alexandrescu, S; Bauer, TW; Buettner, S; Cercek, A; D'Angelica, M; Franssen, S; Gamblin, TC; Jarnagin, WR; Jolissaint, JS; Kemeny, N; Kingham, TP; Koerkamp, BG; Lamelas, J; Maithel, SK; Margonis, GA; Marques, H; Marsh, JW; Pawlik, TM; Poultsides, GA; Pulitano, C; Shen, F; Soares, KC; Tsilimigras, DI; Weiss, MJ, 2022)
"Sarcopenia was prevalent (48%) and was associated with a worse survival (HR 2."	1.48	Implementation and early outcomes for a surgeon-directed hepatic arterial infusion pump program for colorectal liver metastases. ( Abdel-Misih, S; Beal, EW; Bloomston, M; Chafitz, A; Chakedis, J; Davidson, G; Dillhoff, M; Galo, J; Pawlik, TM; Reardon, J; Schmidt, CR; Sun, S, 2018)
"Gemcitabine accumulation was significantly enhanced in fibroblast-rich tumours compared with liver metastases and normal liver."	1.48	Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. ( Bapiro, TE; Chen, N; Ellenrieder, V; Frese, KK; Gopinathan, A; Gress, TM; Hessmann, E; Heuchel, R; Jodrell, DI; Johnsen, SA; Kari, V; Klein, L; Li, X; Löhr, JM; Neesse, A; Patzak, MS; Ramu, I; Richards, FM; Verbeke, C, 2018)
" This study aimed to compare the overall survival (OS) of HAI-FUDR in combination with modern systemic CT versus modern systemic CT alone in patients with IU-CRCLM."	1.46	Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study. ( Bahary, N; Bartlett, DL; Choudry, MH; Clifford, AK; Dhir, M; Hogg, ME; Holtzman, MP; Jones, HL; Perkins, S; Pingpank, JF; Shuai, Y; Steve, J; Zeh, HJ; Zureikat, AH, 2017)
"In all three studies, the incidence of hyperbilirubinemia and biliary stent placement within 1 year of treatment was increased with the addition of Bev."	1.40	Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. ( Allen, P; Capanu, M; Cercek, A; D'Angelica, M; DeMatteo, RP; Fong, Y; Gewirtz, A; Jarnagin, WR; Kemeny, NE; Patel, D; Power, D, 2014)
"Mean time from gastric cancer diagnosis to liver metastasis was significantly longer in the TAI group (n = 13) than in the systemic chemotherapy group (n = 29); 944 ± 231 days versus 506 ± 77 days."	1.38	The effect of locoregional transarterial infusion chemotherapy on liver metastasis after gastric cancer resection. ( Kan, ZX; Liu, R; Qian, S; Wang, JH; Wang, YY; Zhang, W, 2012)
"Although most patients with gestational trophoblastic neoplasia (GTN) are cured by conventional chemotherapy, some develop drug resistance or relapse."	1.37	Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. ( Feng, F; Geng, S; Wan, X; Wang, T; Xiang, Y, 2011)
"To establish a multidrug-resistant hepatocellular carcinoma cell line BEL-7402/5-deoxy-5-fluorouridine (5'-DFUR) and study the mechanisms of the drug resistance."	1.35	[Establishment of a 5-DFUR-resistant human hepatocellular carcinoma cell model and preliminary study of the mechanisms of the drug resistance]. ( Li, RP; Liang, P; Tang, H, 2008)
"Paclitaxel was administered at a dose of 80 mg/m(2) on day 1, 8 and 15, and doxifluridine was orally administered at a dose of 533 mg/m(2) day for five days followed by withdrawal for two days."	1.35	[A case of complete response for advanced gastric cancer with liver metastasis treated with combination chemotherapy of weekly paclitaxel and doxifluridine]. ( Higuchi, T; Iesato, H; Kawate, S; Matsumoto, H; Numaga, Y; Ohya, T; Okabe, T; Tago, K; Takeyoshi, I; Totsuka, O; Yokomori, T, 2009)
"Floxuridine was conjugated to polyethylenimine-beta-cyclodextrin to form prodrug PEI-beta-CyD-Fd."	1.35	[Preparation of floxuridine loaded polycation and its antitumor activity]. ( Chen, D; Jiang, QY; Lu, X; Tang, GP; Wang, QQ; Yu, H; Zhao, DJ; Zhou, J, 2009)
"A 82-year-old man with advanced gastric cancer underwent distal gastrectomy in January 2006."	1.35	[Complete response obtained with first-line therapy as S-1, followed by second-line 5'-DFUR plus paclitaxel therapy in a patient with multiple liver and lymph node metastases from gastric cancer]. ( Kitajima, Y; Miyazaki, K; Nakafusa, Y; Ohtsuka, T; Sato, S; Tanaka, M; Yakabe, T, 2009)
"Gemcitabine was rapidly eliminated from plasma even in patients with renal dysfunction."	1.35	Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer. ( Hirobe, M; Itoh, T; Kunishima, Y; Masumori, N; Takayanagi, A; Takeuchi, M; Tsukamoto, T, 2008)
"Many patients with gastric cancer respond to TS-1, but some fail to respond or have recurrence."	1.34	Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1. ( Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Yasuda, Y; Yokoyama, T; Zuiki, T, 2007)
"In order to develop a model of liver metastasis of human gastrointestinal cancer cells, we examined the potential of 10 human colon and stomach cancer cell lines (HT-29, WiDr, HCT-116, HCT-15, HCC-2998, MKN7, MKN28, MKN45, MKN74 and St-4) to form liver metastases in nude mice."	1.34	Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. ( Ishizu, K; Makuuchi, H; Sadahiro, S; Sunose, N; Tsuruo, T; Yamazaki, K; Yamori, T, 2007)
"Thirty-nine patients with hepatocellular carcinoma were treated with oral 5'-DFUR for more than 4 d before operation."	1.33	5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma. ( Wang, HD; Zheng, JF, 2005)
"The data on 307 patients with colorectal cancer at stage II or III, who underwent potentially curative resection with lymphadenectomy, were reviewed."	1.33	The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. ( Ikeda, S; Ishibashi, N; Matono, K; Mizobe, T; Ogata, Y; Ogo, S; Ohkita, A; Ozasa, H; Sasatomi, T; Shirouzu, K, 2006)
"Two patients with liver metastasis from gastric cancer who responded remarkably to a combined therapy of 5'-DFUR and PSK are reported."	1.31	[Two patients with liver metastasis from gastric cancer who responded remarkably to combined therapy of 5'-DFUR and PSK]. ( Arai, K; Inoue, S; Iwasaki, Y; Kawahara, Y; Kitamura, M; Maeshiro, T; Miyamoto, Y; Ohashi, M; Saiura, A; Takahashi, T; Tanaka, S; Umekita, N, 2000)
"We report a case of advanced gastric cancer with multiple liver metastases and peritoneal dissemination."	1.31	[Effectiveness of high-dose, intermittent 5'-DFUR therapy for advanced gastric cancer]. ( Emoto, K; Etoh, T; Ichiba, Y; Imaoka, Y; Ishizaki, Y; Sumimoto, R; Takahashi, M; Tokumoto, N, 2001)
"She was diagnosed with stage IV breast cancer."	1.31	[Hepatic infusion of docetaxel using PEIT for a patient with stage IV breast cancer]. ( Chino, Y; Ogata, M; Suzuki, Y; Tani, T; Ubukata, N; Yoshihara, K, 2001)
"In a 79-year-old man with ascending colon cancer, multiple liver metastases were detected by computer tomography."	1.31	[A case of colon cancer with multiple liver metastases and lymph nodes metastases successfully treated by 5'-deoxy-5-fluorouridine]. ( Hotokezaka, M; Ishimitsu, T; Matsumoto, S; Nakamura, K; Takeda, S, 2002)
"A total of 22 patients (11 with hepatocellular carcinoma and 11 with cholangiocarcinoma) were treated."	1.30	Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. ( Andrews, JC; Ensminger, WD; Kessler, ML; Lawrence, TS; Robertson, JM; Walker, S, 1997)
"Its efficacy for lung metastases from colorectal cancer is known."	1.30	[PyNPase activity in primary and metastatic colorectal cancer]. ( Doi, O; Furukawa, H; Hiratsuka, M; Imaoka, S; Ishikawa, O; Iwanaga, T; Kabuto, T; Kameyama, M; Nakamori, S; Ohigashi, H; Sasaki, Y; Yasuda, T; Yokouchi, H, 1997)
"Eleven colorectal cancer patients underwent hepatic resection for liver metastasis."	1.30	[Adjuvant intra-arterial chemotherapy with gastrin receptor antagonist after hepatic resection in colorectal cancer metastasis]. ( Furukawa, H; Hiratsuka, M; Imaoka, S; Ishikawa, O; Kabuto, T; Kameyama, M; Murata, K; Nakano, H; Ohigashi, H; Sasaki, Y; Tsugawa, T; Yasuda, T, 1998)
"Multiple liver and lung metastasis of breast cancer were diagnosed because of high CA 15/3 serum levels and normal gastrointestinal study."	1.30	[Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report]. ( Hoshino, K; Ikeda, H; Koyama, T; Morishita, Y; Nakamura, M, 1999)
" The aim of this study was to quantitatively assess spontaneous functional hepatic arteriovenous shunting in patients with liver metastases and to determine its implication in the increase in systemic toxic effects of intra-arterial infusion chemotherapy with floxuridine."	1.30	Sorbitol removal by the metastatic liver: a predictor of systemic toxicity of intra-arterial chemotherapy in patients with liver metastases. ( Alabiso, O; Bar, F; Battista, S; Bucchi, MC; Cappello, N; Gariboldi, A; Grosso, M; Miraglia, S; Molino, G; Zanon, C, 1999)
"We reported a patient with advanced gastric cancer and a liver metastasis, who responded remarkably to combination chemotherapy using THP, 5'-DFUR and CDDP."	1.29	[A case of advanced gastric cancer successfully treated with combination chemotherapy using THP, 5'-DFUR and CDDP, followed by surgical resection]. ( Adachi, H; Kobori, O; Kurihara, M; Kurihara, T; Murakami, H; Saito, K; Tamura, Y, 1995)
"A 71-year-old man with Borrmann type 3 gastric cancer with multiple liver metastases had been treated with 5'-DFUR 1400 mg/m2/day, p."	1.29	[A successful 5'-DFUR and CDDP combination therapy for an advanced gastric cancer complicated with multiple liver metastases]. ( Ishihata, R; Kasukawa, R; Kuwana, T; Nishimaki, T; Obara, K, 1995)
"A 64-year-old male was found to have a gastric cancer (Borrmann type 3) on the posterior wall of the stomach."	1.29	[A case of advanced gastric cancer with liver metastasis disappeared by oral administration of 5'-deoxy-5-fluorouridine after absolute non-curative operation]. ( Matoba, N; Nagata, T; Niiyama, H; Yoshida, J, 1994)
"A 71-year-old male with recurrent colon cancer was admitted to our hospital with obstructive jaundice."	1.29	[A case of recurrent colon cancer treated markedly effective with 5'-DFUR]. ( Hirano, M; Kato, A; Kikkawa, H; Kitagawa, K; Masuda, S; Mori, H; Murakami, N; Oosawa, T; Saito, H; Watanabe, S, 1993)
"A 65-year-old female patient with liver cirrhosis complicated with hepatocellular carcinoma (HCC) was treated with oral administration of 5'-DFUR (600 mg/day)."	1.29	[A case of hepatocellular carcinoma responding to oral administration of 5'-DFUR]. ( Mizuno, M; Ogino, M; Tanaka, Y; Tokuda, H; Yamauchi, M, 1996)
"We experienced 522 patients with breast carcinoma and 14 cases (2."	1.29	[A case resectable hepatic metastases of breast cancer following intrahepatic arterial chemotherapy]. ( Matsumine, T; Matsumoto, J; Minami, T; Takami, M; Takanishi, K, 1996)
"The goals of this study of a hepatic arterial infusion (HAI) regimen of alternating floxuridine and 5-fluorouracil were to evaluate the treatment-related toxic effects, the antitumor response rate, and patient survival."	1.29	Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. ( Chase, JL; Curley, SA; Davidson, BS; DuBrow, RA; Hohn, DC; Izzo, F; Patt, Y, 1996)
"She was diagnosed as having an advanced gastric cancer, which was unresectable because of liver metastasis, esophageal invasion and paraaortic lymph node metastasis."	1.29	[Unresectable gastric cancer followed by remarkably effective tumor disappearance and good quality of life for 10 months after CDDP/5'-DFUR combination chemotherapy--a case report]. ( Hoshino, K; Ikeda, H; Kamoshita, N; Kobayashi, J; Koyama, T; Morishita, Y; Nakamura, M; Tanaka, T, 1996)
"Ten patients with unresectable primary liver cancer, eight of whom had elevated serum alpha-fetoprotein levels, were treated with intrahepatic fluorodeoxyuridine (FUDR) and mitomycin C administered through an implantable pump."	1.28	Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump. ( Atiq, OT; Botet, J; Kemeny, N; Niedzwiecki, D, 1992)
"We describe a case of gastric cancer with multiple liver metastasis that clearly decreased in size after administration of 5'-DFUR."	1.28	[A case report; 5'-DFUR reduced gastric cancer with multiple liver metastasis]. ( Itoh, N; Kurimoto, N; Tamura, T; Yasuzawa, Y; Yoshimoto, I, 1992)
"injection against mouse colon cancer, colon 26."	1.28	[Antitumor activity of T-506, a novel synthetic FUDR derivative, on murine colon cancer and its hepatic metastasis]. ( Fujimaki, M; Kurokawa, M; Kuroki, Y; Ochiai, H; Okamoto, M; Tazawa, K; Yamashita, I, 1991)
"The tumor did not recur, but sclerosing cholangitis and liver failure developed which necessitated orthotopic liver transplantation."	1.28	Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? ( Kim, CH; Krom, RA; Ludwig, J; Wiesner, RH, 1989)
"The cases of primary hepatic cancer are 2 cases of hepatoma (413, 420 days) and 1 case of cancer of bile-duct (400 days)."	1.28	[Evaluation of long survival cases treated with intra-arterial cancer chemotherapy using implantable reservoirs]. ( Katsuki, Y; Nishimura, A; Tsuji, Y; Yasuda, T, 1989)
"Twelve of the patients had primary hepatocellular carcinoma and six had metastatic liver carcinoma originating from an unknown primary site."	1.27	Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. ( Benjamin, RS; Chuang, VP; Fuqua, R; Mavligit, GM; Patt, YZ; Wallace, S, 1983)
" A dosage of 0."	1.27	Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. ( Boxt, LM; Garnick, MB; Kandarpa, K; Kaplan, WD; Mayer, RJ; Osteen, RT; Schade, D; Steele, GD; Weiss, GR; Wilson, RE, 1983)
"Retreatment of patients with colon cancer and liver metastases by hepatic arterial infusion of fluorodeoxyuridine and mitomycin C can result in significant prolongation of survival in patients with response to this treatment."	1.27	Effective retreatment of patients with colorectal cancer and liver metastases. ( Chuang, VP; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1983)
"In patients with metastatic colorectal cancer involving only the liver, hepatic arterial FUDR alone and with the addition of mitomycin C provided excellent control of hepatic tumor."	1.27	Regional chemotherapy of colorectal cancer metastatic to the liver. ( Cozzi, E; Ensminger, W; Gyves, J; Niederhuber, JE; Thrall, J; Walker, S, 1984)
"We found that this conversion in human tumors was catalyzed not by uridine phosphorylase but by thymidine phosphorylase."	1.27	[5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues]. ( Hara, Y, 1984)
"Three patients with primary hepatocellular carcinoma demonstrated less than 50% reduction in tumor size."	1.27	Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump. ( Jones, LS; McCune, CS; Schwartz, SI, 1985)
"Floxuridine (5-FUDR) is an antipyrimidine used in the treatment of metastatic colorectal carcinoma."	1.27	Radiologic manifestations of small-bowel toxicity due to floxuridine therapy. ( Gluck, WL; Gramm, HF; Kelvin, FM; Lokich, JJ, 1986)
" The authors suggest investigation of an alternate drug schedule and/or dosage of floxuridine to eliminate or minimize this serious complication."	1.27	Fibrosis of extrahepatic biliary system after continuous hepatic artery infusion of floxuridine through an implantable pump (Infusaid pump). ( Gourley, WK; Haq, MM; Peterson, DF; Valdes, LG, 1986)
" Toxic effects were hepatocyte necrosis, steatosis, cholestasis, central vein sclerosis, and alterations in the portal triad."	1.27	Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR. ( Doria, MI; Levin, B; Riddell, RH; Shepard, KV, 1986)
"Twenty patients with colon cancer metastatic to the liver underwent successful hepatic resection and adjuvant perioperative therapy that included hepatic arterial mitomycin C and floxuridine (FUDR)."	1.27	Adjuvant perioperative hepatic arterial mitomycin C and floxuridine combined with surgical resection of metastatic colorectal cancer in the liver. ( Ames, FC; Boddie, AW; Charnsangavej, C; Claghorn, LJ; Cleary, KR; Mavligit, GM; McBride, CM; Patt, YZ, 1987)
"Chemical cholecystitis has been recognized recently as a complication of hepatic artery infusion chemotherapy."	1.27	Hepatobiliary scintigraphy in patients receiving hepatic artery infusion chemotherapy. ( Dakhil, SR; Housholder, DF; Hynes, HE; Marymont, JV, 1985)
"Forty patients with colorectal cancer metastatic to the liver were treated with an implanted pump for hepatic artery perfusion."	1.27	The implanted pump in metastatic colorectal cancer of the liver. Risk versus benefit. ( Johnson, LP; Rivkin, SE, 1985)
"Thirty-five patients with metastatic colon cancer received hepatic arterial FUDR administered with implanted infusion pumps."	1.27	Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2'-deoxyuridine. ( Hohn, DC; Lewis, BJ; Price, DC; Stagg, RJ, 1985)
"Of 13 patients with hepatoma, nine had clinically significant regression with a median survival of 11 months."	1.26	The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. ( Al-Sarraf, M; Baker, L; Izbicki, R; Reed, ML; Sexon-Porte, M; Singhakowinta, A; Straatsma, GW; Vaitkevicius, VK; Vaughn, CB, 1981)
"Forty-eight patients with liver metastases were treated at Rhode ISland Hospital in a nonrandomized sequential manner between January 1972 and June 1977."	1.26	A combined treatment approach to management of hepatic metastasis. ( Glicksman, AS; Leone, LA; Rege, VB; Soderberg, CH; Webber, BM, 1978)
"Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts."	1.25	Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975)

Research

Studies (523)

Authors

Clinical Trials (14)

Trial Overview

Trial Outcomes

Number of Participants With Intrahepatic Disease Progression After Treatment With Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

Timeframe	Studies, this research(%)	All Research%
pre-1990	231 (44.17)	18.7374
1990's	125 (23.90)	18.2507
2000's	119 (22.75)	29.6817
2010's	36 (6.88)	24.3611
2020's	12 (2.29)	2.80

Authors	Studies
Rico, L	1
Østergaard, ME	1
Bell, M	1
Seth, PP	1
Hanessian, S	1
Holster, JJ	2
El Hassnaoui, M	1
Franssen, S	2
IJzermans, JNM	1
de Jonge, J	1
Mostert, B	1
Polak, WG	1
de Wilde, RF	1
Homs, MYV	3
Groot Koerkamp, B	2
Walker, BS	1
Billingsley, KG	1
Sutton, TL	1
Kolbeck, KJ	1
Korngold, EK	1
Nabavizadeh, N	1
Dewey, EN	1
Herzig, DO	1
Lopez, CD	1
Mayo, SC	1
Soares, KC	1
Jolissaint, JS	1
Tsilimigras, DI	1
Buettner, S	1
Alexandrescu, S	1
Marques, H	1
Lamelas, J	1
Aldrighetti, L	2
Gamblin, TC	1
Maithel, SK	1
Pulitano, C	2
Margonis, GA	1
Weiss, MJ	1
Bauer, TW	1
Shen, F	1
Poultsides, GA	1
Marsh, JW	2
Cercek, A	8
Kemeny, N	28
Kingham, TP	4
D'Angelica, M	7
Pawlik, TM	2
Jarnagin, WR	14
Koerkamp, BG	2
Elijah, J	1
Schepers, AJ	1
Krauss, JC	1
McDevitt, RL	1
Lumish, M	1
Thackray, J	1
Do, RKG	2
Caudle, KE	1
Amstutz, U	1
Schwab, M	1
Diasio, RB	1
IJzerman, NS	2
Filipe, WF	2
Bruijn, P	1
Buisman, FE	2
Doorn, LV	1
Doornebosch, PG	2
Grootscholten, C	2
Grünhagen, DJ	2
van Bommel, CPE	1
Kok, NFM	2
Verhoef, C	2
Kuhlmann, KFD	2
Mathijssen, RHJ	2
Koolen, SLW	1
McDonald, HG	1
Patel, RA	1
Ellis, CS	1
Gholami, S	1
Barry-Hundeyin, M	1
Pandalai, PK	1
Kim, J	1
Cavnar, MJ	1
Peng, X	1
Gao, J	1
Yuan, Y	2
Liu, H	1
Lei, W	1
Li, S	2
Zhang, J	1
Wang, S	3
Boerner, T	1
Tan, BR	1
Chou, JF	4
Gönen, M	9
Boucher, TM	3
Hauser, HF	1
Lowery, MA	1
Harding, JJ	1
Varghese, AM	1
Reidy-Lagunes, D	2
Saltz, L	2
Schultz, N	1
D'Angelica, MI	8
DeMatteo, RP	8
Drebin, JA	1
Allen, PJ	6
Balachandran, VP	1
Lim, KH	1
Sanchez-Vega, F	1
Vachharajani, N	1
Majella Doyle, MB	1
Fields, RC	1
Hawkins, WG	1
Strasberg, SM	1
Chapman, WC	1
Diaz, LA	1
Kemeny, NE	16
Peng, C	1
Zhou, C	1
Li, G	1
Li, H	1
Shi, L	3
Xue, F	1
Lin, X	2
Cai, Z	1
Liu, X	1
Ma, Y	1
Wu, M	1
Ha, NB	1
Wang, CW	1
El-Nachef, N	1
Zhang, H	1
Xu, H	1
Tang, Q	1
Bi, F	1
Dhir, M	2
Zenati, MS	1
Jones, HL	2
Bartlett, DL	3
Choudry, MHA	1
Pingpank, JF	2
Holtzman, MP	2
Bahary, N	2
Hogg, ME	2
Zeh, HJ	2
Geller, DA	2
Wallis Marsh, J	1
Tsung, A	1
Zureikat, AH	2
Wei, N	1
Zhang, B	2
Wang, Y	1
He, XH	1
Xu, LC	1
Li, GD	1
Wang, YH	1
Wang, GZ	1
Huang, HZ	1
Li, WT	1
Chakedis, J	1
Beal, EW	1
Sun, S	1
Galo, J	1
Chafitz, A	1
Davidson, G	1
Reardon, J	1
Dillhoff, M	1
Abdel-Misih, S	1
Bloomston, M	1
Schmidt, CR	1
Bennink, RJ	1
Besselink, MGH	1
Borel Rinkes, IHM	1
Bruijnen, RCG	1
van Delden, OM	1
Donswijk, ML	1
van Doorn, L	1
Emmering, J	1
Erdmann, JI	1
Hagendoorn, J	1
Klompenhouwer, EG	1
Koolen, S	1
Kuiper, MC	1
Lam, MGE	1
Moelker, A	1
Oomen-de Hoop, E	1
Punt, CJA	1
Te Riele, WW	1
Roodhart, JML	1
Swijnenburg, RJ	1
Prevoo, W	1
Tanis, PJ	1
Vermaas, M	1
Versleijen, MWJ	1
Veuger, FP	1
Weterman, MJ	1
Power, D	1
Capanu, M	6
Gewirtz, A	1
Patel, D	2
Allen, P	2
Fong, Y	14
Allard, MA	1
Malka, D	1
DʼAngelica, MI	1
Correa-Gallego, C	1
Paty, PB	4
Gewirtz, AN	2
Zhao, C	1
Wang, XJ	1
Feng, WH	1
Yu, CP	1
He, N	1
Li, W	2
Wu, PH	1
Strobel, O	1
Büchler, MW	1
Li, C	1
Gu, Y	1
Zhao, M	1
Wang, F	1
Wang, Z	1
Luo, H	1
Chen, C	1
Chen, G	1
Ding, P	1
Wu, X	1
Lu, Z	1
Pan, Z	1
Xu, R	1
He, Y	1
Wan, D	1
Li, Y	1
Li, X	2
Wu, J	1
Ji, M	1
Zhao, J	2
Qiang, W	1
Ding, W	1
Jiang, J	1
Lu, Q	1
Wu, C	1
Fong, YC	1
Shilkrut, M	1
Sapir, E	1
Hanasoge, S	1
Schipper, MJ	1
Normolle, DP	1
Ben-Josef, E	2
Ensminger, W	4
Lawrence, TS	9
Feng, M	1
Shuai, Y	1
Clifford, AK	1
Perkins, S	1
Steve, J	1
Choudry, MH	1
Gluskin, JS	1
Aguiló, A	1
Connell, LC	1
Hessmann, E	1
Patzak, MS	1
Klein, L	1
Chen, N	1
Kari, V	1
Ramu, I	1
Bapiro, TE	1
Frese, KK	1
Gopinathan, A	1
Richards, FM	1
Jodrell, DI	1
Verbeke, C	1
Heuchel, R	1
Löhr, JM	1
Johnsen, SA	1
Gress, TM	1
Ellenrieder, V	1
Neesse, A	1
Martínez C, J	1
Jarufe C, N	1
González D, R	1
Alvarez Z, M	1
Power, DG	3
Healey-Bird, BR	1
Tang, H	1
Liang, P	1
Li, RP	1
Khan, AZ	1
Morris-Stiff, G	1
Makuuchi, M	1
Okabe, T	1
Ohya, T	1
Matsumoto, H	2
Tago, K	1
Totsuka, O	1
Numaga, Y	1
Higuchi, T	1
Iesato, H	1
Yokomori, T	1
Kawate, S	1
Takeyoshi, I	1
Jarnagin, W	3
Haviland, D	4
Dematteo, R	2
Zhao, DJ	1
Lu, X	1
Jiang, QY	1
Chen, D	1
Zhou, J	3
Yu, H	1
Wang, QQ	1
Tang, GP	1
Kitajima, Y	1
Yakabe, T	1
Ohtsuka, T	1
Tanaka, M	1
Sato, S	1
Nakafusa, Y	1
Miyazaki, K	2
Melendez, FD	1
Schwartz, LH	4
Gultekin, DH	2
Shia, J	2
Tse, A	1
Blumgart, LH	4
Mocellin, S	2
Pasquali, S	1
Nitti, D	3
Townsend, A	1
Price, T	1
Karapetis, C	1
Pilati, P	1
Mammano, E	1
Tessari, E	1
Lise, M	2
Alberts, SR	2
Roh, MS	2
Mahoney, MR	2
O'Connell, MJ	6
Nagorney, DM	4
Wagman, L	1
Smyrk, TC	1
Weiland, TL	1
Lai, LL	1
Schwarz, RE	1
Molina, R	1
Dentchev, T	1
Bolton, JS	4
Chen, Y	2
Yan, Z	2
Wang, J	3
Wang, X	2
Luo, J	2
Liu, Q	2
Nukaya, H	1
Kajino, S	1
Tokuda, H	2
Tanaka, Y	4
Hasegawa, I	1
Kato, A	2
Joh, T	1
Samaras, P	1
Breitenstein, S	1
Haile, SR	1
Stenner-Liewen, F	1
Heinrich, S	3
Feilchenfeldt, J	1
Renner, C	1
Knuth, A	2
Pestalozzi, BC	2
Clavien, PA	5
Feng, F	1
Xiang, Y	1
Wan, X	1
Geng, S	1
Wang, T	1
Yopp, AC	1
Bamboat, Z	1
Schwartz, L	3
Yopp, A	1
Gultekin, D	1
Farr, GH	1
Fitch, TR	1
Maples, WJ	1
Rubin, J	2
Fuloria, J	1
Steen, PD	1
House, MG	1
Ito, K	1
Ito, H	1
Ji, S	1
Xu, J	2
Xu, Y	1
Liu, C	1
Long, J	1
Ni, Q	1
Yu, X	1
Baek, YH	1
Kim, KT	1
Lee, SW	1
Jeong, JS	1
Park, BH	1
Nam, KJ	1
Cho, JH	1
Kim, YH	1
Roh, YH	1
Lee, HS	1
Choi, YM	1
Han, SY	1
Wang, YY	1
Zhang, W	1
Qian, S	1
Liu, R	1
Kan, ZX	1
Wang, JH	2
Yin, C	1
Tang, G	1
Wu, Q	1
Di Stefano, G	2
Busi, C	2
Fiume, L	2
Takizawa, M	1
Hirano, M	2
Murakami, N	2
Uno, Y	1
Kikuchi, T	1
Nozawa, H	1
Hara, T	1
Asaumi, Y	1
Kikkawa, H	2
Cheng, J	1
Glasgow, RE	1
O'Rourke, RW	1
Swanstrom, LL	1
Hansen, PD	1
Bilchik, AJ	3
Wood, TF	2
Chawla, SP	2
Rose, DM	1
Chung, MH	1
Stern, SS	1
Foshag, LJ	2
Ramming, KP	5
Barnett, KT	1
Malafa, MP	1
Petrowsky, H	2
Schwinnen, I	1
Staib-Sebler, E	3
Gog, C	3
El-Ganainy, A	1
Gutt, C	1
Müller, HH	5
Lorenz, M	14
Bonetti, A	1
Janciauskiene, R	1
Juozaityte, E	1
Pavalkis, D	1
Feun, LG	1
O'Brien, C	1
Molina, E	1
Rodriguez, M	1
Jeffers, L	1
Schiff, ER	1
Marini, A	1
Savaraj, N	1
Ardalan, B	1
Brooks, A	1
Clingan, P	1
Morris, D	1
Dahm, F	1
Selzner, N	3
Selzner, M	4
Onaitis, M	1
Morse, M	2
Hurwitz, H	1
Cotton, P	1
Tyler, D	1
Clavien, P	1
Clary, B	1
Sakaguchi, Y	1
Kabashima, A	1
Kuma, S	1
Kajiyama, K	1
Kapoor, V	1
Brancatelli, G	1
Federle, MP	1
Katyal, S	1
Stockman, J	4
Blumgart, L	1
Sperber, D	1
Hummer, A	1
Alimonti, A	1
Ferretti, G	1
Di Cosimo, S	1
Cognetti, F	1
Vecchione, A	1
DAO, TL	1
GRINBERG, R	1
SULLIVAN, RD	3
NORCROSS, JW	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver[NCT03366155]	Phase 2	40 participants (Anticipated)	Interventional	2019-06-24	Recruiting
A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Bes[NCT00492999]	Phase 2	64 participants (Anticipated)	Interventional	2007-05-31	Active, not recruiting
A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer[NCT00008294]	Phase 1	0 participants	Interventional	2000-08-31	Completed
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma[NCT01525069]	Phase 1	27 participants (Actual)	Interventional	2012-04-03	Terminated (stopped due to Equipment that was used in the study was discontinued)
A Phase II Trial Evaluating Multiple Metastasectomy Combined With Hepatic Artery Infusion Of Floxuridine (FUDR) And Dexamethasone (DXM), Alternating With Systemic Oxaliplatin (OXAL) And Capecitabine (CAPCIT) For Colorectal Carcinoma Metastatic To The Live[NCT00026234]	Phase 2	75 participants (Actual)	Interventional	2002-02-28	Completed
A Phase II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Bevacizumab (A Monoclonal Antibody to Vascular Endothelial Growth Factor-A), in Patients With Unresectable Primary Hepatic Malignancy[NCT00410956]	Phase 2	55 participants (Anticipated)	Interventional	2007-05-31	Active, not recruiting
A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681]	Phase 2	6 participants (Actual)	Interventional	2014-09-30	Terminated (stopped due to lack of funding)
A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases[NCT01042691]	Phase 1	10 participants (Actual)	Interventional	2003-05-31	Completed
A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006[NCT00701168]		0 participants	Expanded Access		No longer available
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver[NCT00001576]	Phase 1	28 participants	Interventional	1997-07-31	Completed
A Phase III Randomized Trial of Standard Dose Stereotactic Body Radiation Therapy (SBRT) Versus Radiobiologically-Guided Dose Selected SBRT In Primary or Secondary Liver Carcinoma (SAVIOR).[NCT04745390]		110 participants (Anticipated)	Interventional	2021-08-01	Recruiting
Short-term Effects of Laparoscopic-assisted Small-incision Surgery Versus Conventional Laparotomy in Treatment of Resectable Colorectal Liver Metastasis[NCT02350166]	Phase 3	40 participants (Anticipated)	Interventional	2013-11-30	Recruiting
Human Liver Explants for HIF-1 Alpha- Analysis/Comparison[NCT00866957]		180 participants (Actual)	Observational	2006-02-28	Completed
Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449]	Phase 3	338 participants (Actual)	Interventional	2012-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.

Number of Participants With Intrahepatic Recurrence After Partial Hepatectomy With Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

Intervention	Participants (Count of Participants)
Treatment	6

To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.

Number of Participants With Post-operative Complications After Partial Hepatectomy After Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

Intervention	Participants (Count of Participants)
Treatment	1

Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy

Article	Year
Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Annals of surgical oncology, 2022, Volume: 29, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chola	2022
Place of hepatic intra-arterial chemotherapy in the treatment of colorectal liver metastases. Journal of visceral surgery, 2014, Volume: 151 Suppl 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A	2014
[Current therapeutic options for liver metastasis]. Revista medica de Chile, 2008, Volume: 136, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Catheter Ablation; Colorect	2008
Regional chemotherapy for liver-limited metastatic colorectal cancer. Clinical colorectal cancer, 2008, Volume: 7, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo	2008
Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. Journal of hepato-biliary-pancreatic surgery, 2009, Volume: 16, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit	2009
The role of floxuridine in metastatic liver disease. Molecular cancer therapeutics, 2009, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial;	2009
Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm	2009
Selective internal radiation therapy for liver metastases from colorectal cancer. The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4 Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluor	2009
Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. Critical reviews in oncology/hematology, 2011, Volume: 79, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Camptothecin; Chemotherapy, Adju	2011
Management of a malignant case of solid pseudopapillary tumor of pancreas: a case report and literature review. Pancreas, 2012, Volume: 41, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Female;	2012
Complications of hepatic artery infusion: a review of 4580 reported cases. International journal of gastrointestinal cancer, 2001, Volume: 30, Issue:3 Topics: Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Bone Marrow Diseases; Catheters, Indwe	2001
[The role of the regional (intra-arterial) chemotherapy in the treatment of hepatic metastases of colorectal cancer]. Medicina (Kaunas, Lithuania), 2003, Volume: 39, Issue:1 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic	2003
Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: an update. Surgical oncology clinics of North America, 2003, Volume: 12, Issue:1 Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Flox	2003
Review article: colorectal cancer chemotherapy. Alimentary pharmacology & therapeutics, 2003, Oct-01, Volume: 18, Issue:7 Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Ne	2003
[A case of 10-year survival after combination chemotherapy of 5'-deoxy-5-fluorouridine and cisplatin and adjuvant surgery for gastric cancer with liver metastasis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:2 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality	2004
Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions. The Surgical clinics of North America, 2004, Volume: 84, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Colorectal Neoplasms; Dose-Response Relationship,	2004
Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:6 Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Fluorour	2004
Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. Cancer treatment reviews, 2004, Volume: 30, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flo	2004
Intraarterial hepatic infusion chemotherapy in metastatic liver cancer. Seminars in oncology, 1983, Volume: 10, Issue:2 Topics: Antineoplastic Agents; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusio	1983
Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma. Seminars in oncology, 1983, Volume: 10, Issue:2 Topics: Antineoplastic Agents; Catheterization; Colonic Neoplasms; Drug Therapy, Combination; Floxuridine; F	1983
Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. Annals of internal medicine, 1984, Volume: 100, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Floxuridin	1984
Hepatic intraarterial chemotherapy--current status and future prospects--"If you have a short sword, take a step forward". Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:5 Topics: Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Doxorubicin; Floxuridine; Hepatic Art	1983
Treatment of liver metastasis from colon cancer. Missouri medicine, 1981, Volume: 78, Issue:12 Topics: Catheterization; Colonic Neoplasms; Floxuridine; Hepatic Artery; Humans; Liver Neoplasms; Mitomycins	1981
[Results of resection and adjuvant therapy of liver metastases of primary colorectal tumors--a review of the literature]. Zentralblatt fur Chirurgie, 1995, Volume: 120, Issue:10 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regiona	1995
[What is the value of arterial chemotherapy in treatment of colorectal liver metastases]. Langenbecks Archiv fur Chirurgie, 1994, Volume: 379, Issue:6 Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Floxu	1994
[Adjuvant and palliative regional therapy of liver metastases in colorectal tumors]. Deutsche medizinische Wochenschrift (1946), 1995, May-12, Volume: 120, Issue:19 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region	1995
Update on regional treatments for hepatobiliary malignancies. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular;	1995
Hepatic artery chemotherapy for colorectal liver metastases. The Australian and New Zealand journal of surgery, 1995, Volume: 65, Issue:6 Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infu	1995
Hepatic arterial chemotherapy for metastatic colorectal carcinoma. British journal of cancer, 1994, Volume: 69, Issue:2 Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial;	1994
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Journal of the National Cancer Institute, 1996, Mar-06, Volume: 88, Issue:5 Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Health Care Costs;	1996
Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer, 1996, Oct-15, Volume: 78, Issue:8 Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms;	1996
Hepatic arterial infusion for metastatic colorectal cancer: the price of "success". The American journal of gastroenterology, 1996, Volume: 91, Issue:11 Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu	1996
Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. Journal of the National Cancer Institute, 1997, Jun-04, Volume: 89, Issue:11 Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cost-Benefit Analysis; Decision Making; Drug	1997
Antiblastic drug targeting to hepatocellular carcinoma cells: a potential therapeutic improvement? Italian journal of gastroenterology and hepatology, 1998, Volume: 30, Issue:2 Topics: Amino Sugars; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco	1998
Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? Seminars in oncology, 1998, Volume: 25, Issue:5 Suppl 11 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Floxuridine; Flu	1998
Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C. Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug	1999
Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo	1999
Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries. Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera, 2000, Volume: 6, Issue:1 Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Follow-Up Studies;	2000
Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. Oncology, 2000, Volume: 59, Issue:2 Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu	2000
[The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer]. Nihon Geka Gakkai zasshi, 2000, Volume: 101, Issue:8 Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatectomy; Hepat	2000
[Hepatic arterial infusion chemotherapy for liver metastases from colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:14 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fema	2000
Therapeutic approaches to metastasis confined to the liver. Current oncology reports, 2001, Volume: 3, Issue:2 Topics: Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Colorectal	2001
[Evidence for and practical use of arterial infusion chemotherapy for liver metastases]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;	2002
Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Seminars in oncology, 2002, Volume: 29, Issue:2 Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fl	2002
Intrahepatic arterial infusion of chemotherapy: clinical results. Seminars in oncology, 2002, Volume: 29, Issue:2 Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluor	2002
Nonsystemic treatment of metastatic tumors of the liver--a review. Medical and pediatric oncology, 1978, Volume: 4, Issue:3 Topics: Antineoplastic Agents; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial;	1978
Review of regional therapy of liver metastases in colorectal cancer. Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3 Topics: Colorectal Neoplasms; Floxuridine; Hepatic Artery; Humans; Infusion Pumps; Infusions, Intra-Arterial	1992
Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes! Important advances in oncology, 1992 Topics: Actuarial Analysis; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dexamethasone; Fl	1992
Is hepatic infusion of chemotherapy effective treatment for liver metastases? No! Important advances in oncology, 1992 Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Forecasting; Humans; Infusio	1992
[Intra-arterial and intravenous chemotherapy in the treatment of hepatic metastases of colorectal origin: review of the literature and preliminary results]. Revue medicale de Liege, 1990, Volume: 45, Issue:3 Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery	1990
[Treatment of hepatic metastases]. Presse medicale (Paris, France : 1983), 1990, Jun-16, Volume: 19, Issue:24 Topics: Adult; Aged; Female; Floxuridine; Fluorouracil; Hepatectomy; Humans; Infusion Pumps, Implantable; In	1990
[Intra-arterial chemotherapy of the liver]. Wiener medizinische Wochenschrift (1946), 1990, Apr-30, Volume: 140, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Floxuridine; Fluorouracil; He	1990
[Interdisciplinary therapy concepts in primary and secondary neoplasms of the liver]. Zeitschrift fur Gastroenterologie. Verhandlungsband, 1989, Volume: 24 Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Floxuridine; Fluorouracil; Follow-Up Studies;	1989
Colorectal liver metastases: is 'no treatment' still best? Journal of the Royal Society of Medicine, 1989, Volume: 82, Issue:1 Topics: Colonic Neoplasms; Floxuridine; Humans; Liver Neoplasms; Rectal Neoplasms	1989
Infusional versus systemic chemotherapy for liver metastases from colorectal cancer. The Surgical clinics of North America, 1989, Volume: 69, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Hepatic Artery; Humans; Infus	1989
[Current results and prospects of intra-arterial chemotherapy in hepatic metastases of carcinoma of the colorectum]. La Clinica terapeutica, 1989, Sep-30, Volume: 130, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Flox	1989
Treatment of colorectal hepatic metastases. Surgery, gynecology & obstetrics, 1985, Volume: 161, Issue:6 Topics: Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; F	1985
[Therapy concepts in colorectal liver metastases. What is proven, what is open to discussion?]. Leber, Magen, Darm, 1988, Volume: 18, Issue:6 Topics: Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluorouracil; Hepatectomy; Humans; Inf	1988
Adjuvant cytotoxic chemotherapy for colorectal cancer: the present position. The Australian and New Zealand journal of surgery, 1988, Volume: 58, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine	1988
Hepatic artery infusion for metastatic neoplastic disease. Surgery, gynecology & obstetrics, 1985, Volume: 160, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Collateral Circul	1985
[Chemotherapy of cancer of the rectum and the colon]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1970, Nov-16, Volume: 25, Issue:46 Topics: Antimetabolites; Colonic Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Humans; Injections, I	1970
5-Fluorouracil in the treatment of gastrointestinal neoplasia. The New England journal of medicine, 1973, Jan-25, Volume: 288, Issue:4 Topics: Administration, Oral; Antineoplastic Agents; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms;	1973

Article	Year
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA oncology, 2020, Jan-01, Volume: 6, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;	2020
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial. BMC cancer, 2019, Apr-05, Volume: 19, Issue:1 Topics: Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic;	2019
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Annals of surgery, 2015, Volume: 261, Issue:2 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap	2015
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Annals of surgery, 2015, Volume: 261, Issue:2 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap	2015
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Annals of surgery, 2015, Volume: 261, Issue:2 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap	2015
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Annals of surgery, 2015, Volume: 261, Issue:2 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap	2015
[Hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: a phase II trial]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2014, Volume: 85, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flo	2014
Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; China; Colorectal Neoplas	2014
Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases. American journal of clinical oncology, 2018, Volume: 41, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Chemoembolization, Therap	2018
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;	2009
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bi	2009
Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI- Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-10, Volume: 28, Issue:5 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cat	2010
Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer. Anticancer research, 2010, Volume: 30, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therap	2010
Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Annals of surgical oncology, 2011, Volume: 18, Issue:8 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antigens, Neopl	2011
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology, 2011, Volume: 80, Issue:3-4 Topics: Aged; Alkaline Phosphatase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplasti	2011
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52. Clinical colorectal cancer, 2012, Volume: 11, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop	2012
Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Annals of surgery, 2011, Volume: 254, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot	2011
Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer. Onkologie, 2012, Volume: 35, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl	2012
Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. Clinical colorectal cancer, 2001, Volume: 1, Issue:1 Topics: Antimetabolites, Antineoplastic; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regiona	2001
Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial. Journal of cancer research and clinical oncology, 2003, Volume: 129, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin;	2003
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Sep-01, Volume: 21, Issue:17 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp	2003
The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine. European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:10 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Enzyme-Linked Immu	2004
The efficacy of long-term oral chemotherapy with 5'-deoxy-5-fluorouridine and cyclophosphamide for recurrent breast cancer. International journal of clinical oncology, 2004, Volume: 9, Issue:5 Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast	2004
Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer. Chemotherapy, 2005, Volume: 51, Issue:1 Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl	2005
Improved hepatic toxicity profile of portal vein adjuvant hepatic infusional chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-01, Volume: 23, Issue:22 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemot	2005
Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. Journal of surgical oncology, 2005, Aug-01, Volume: 91, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dexamethasone; Dose-	2005
Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, In	2005
Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Annals of surgery, 2007, Volume: 245, Issue:4 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol	2007
[Efficacy of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma: a controlled randomized trial]. Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:8 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Chemoemboliza	2007
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Japanese journal of clinical oncology, 2008, Volume: 38, Issue:3 Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free	2008
Chemotherapy of large bowel cancer. Cancer, 1982, Dec-01, Volume: 50, Issue:11 Suppl Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Floxuridine; Fluorouraci	1982
A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Annals of surgery, 1983, Volume: 198, Issue:5 Topics: Clinical Trials as Topic; Colonic Neoplasms; Female; Floxuridine; Humans; Infusions, Intra-Arterial;	1983
Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet (London, England), 1994, Nov-05, Volume: 344, Issue:8932 Topics: Anxiety; Aspartate Aminotransferases; Bilirubin; Carcinoembryonic Antigen; Cause of Death; Colorecta	1994
Treatment of hepatic-metastatic colorectal cancer with a chemotherapeutic emulsion: interim results of a phase I trial. Annals of surgical oncology, 1995, Volume: 2, Issue:4 Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Emulsions; Female; Floxuridine; Hepatic	1995
The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy. International journal of radiation oncology, biology, physics, 1995, May-15, Volume: 32, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Combined Modality Therapy; Female; Floxuridine	1995
[The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient]. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B	1995
[Combination with intra-hepatic arterial infusion of low-dose cisplatin and oral administration of high-dose doxyfluridine in patients with liver metastases of gastric cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ	1994
[Hepatic arterial infusion after hepatectomy for liver metastases of colorectal carcinoma to prevent residual hepatic recurrence]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Floxuridine; Flu	1994
[Adjuvant chemo-endocrine chemotherapy with gastrin antagonist after resection of liver metastasis in colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj	1994
Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Colorecta	1994
Gastric mucosal injury after hepatic arterial infusion chemotherapy with floxuridine. A clinical and pathologic study. Cancer, 1994, Apr-15, Volume: 73, Issue:8 Topics: Adult; Aged; Biopsy; Colonic Neoplasms; Female; Floxuridine; Gastric Mucosa; Gastritis; Hepatic Arte	1994
Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubi	1994
Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. Cancer, 1994, Feb-15, Volume: 73, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Drug A	1994
Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorect	1993
A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. Cancer, 1993, Mar-15, Volume: 71, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop	1993
[Quality of life and survival after continuous intrahepatic floxuridine infusions in liver metastases of colorectal carcinomas]. Zeitschrift fur Gastroenterologie, 1995, Volume: 33, Issue:11 Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Follow-Up Studies; Humans; Infusions, Int	1995
Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hum	1997
Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:4 Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents	1997
Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer letters, 1997, Sep-16, Volume: 118, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomar	1997
Differential device performances for hepatic arterial chemotherapy: a technical report on totally implantable pumps and ports for both continuous and bolus infusion. European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 1998, Volume: 30, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Floxuridine; Humans; Infusion Pump	1998
Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:6 Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Floxuridine; Humans; Liver Neoplasms; Mo	1998
Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv	1998
Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. British journal of cancer, 1998, Volume: 78, Issue:8 Topics: Colorectal Neoplasms; Drug Resistance, Neoplasm; Floxuridine; Fluorouracil; Hepatic Artery; Humans;	1998
[Intra-arterial (5-FU/FA and FUDR) versus systemic chemotherapy (5-FU/FA) of non-resectable colorectal liver metastases]. Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress, 1998, Volume: 115 Topics: Adult; Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; F	1998
Phase II evaluation of treatment of complete resection of hepatic metastases from colorectal cancer and adjuvant hepatic arterial infusion of floxuridine: an Eastern Cooperative Oncology Group Study (PB083). American journal of clinical oncology, 1999, Volume: 22, Issue:3 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female;	1999
Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. Anti-cancer drugs, 1999, Volume: 10, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Clocks; Colonic Neoplasms; C	1999
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. The New England journal of medicine, 1999, Dec-30, Volume: 341, Issue:27 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C	1999
Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P	2000
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect	2000
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect	2000
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect	2000
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect	2000
Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastases. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2000, Volume: 26, Issue:5 Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neopl	2000
Phase I clinical trial of oral furtulon and combined hepatic arterial chemoembolization and radiotherapy in unresectable primary liver cancers, including clinicopathologic study. American journal of clinical oncology, 2000, Volume: 23, Issue:5 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoe	2000
Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study. Oncology, 2000, Volume: 59, Issue:3 Topics: Administration, Oral; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellu	2000
Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery, 2001, Volume: 129, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio	2001
Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, May-15, Volume: 19, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ca	2001
Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:12 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Di	2001
Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Annals of surgical oncology, 2002, Volume: 9, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; California; Camptothecin; Colorectal	2002
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-15, Volume: 20, Issue:6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm	2002
Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil. Cancer treatment reports, 1976, Volume: 60, Issue:9 Topics: Adult; Aged; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Injection	1976
Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:7 Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Floxuridine; Hepatic Artery; Humans; Inf	1992
A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer, 1992, Jan-15, Volume: 69, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dexamethasone; Do	1992
Evaluation of oil-soluble FUdR ester for transcatheter arterial treatment of hepatomas. Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:5 Topics: Carcinoma, Hepatocellular; Catheters, Indwelling; Chemoembolization, Therapeutic; Doxorubicin; Drug	1992
Continuous regional treatment with fluoropyrimidines for metastases from colorectal carcinomas: influence of modulation with leucovorin. Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3 Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Hepatic Arter	1992
Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes! Important advances in oncology, 1992 Topics: Actuarial Analysis; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dexamethasone; Fl	1992
Is hepatic infusion of chemotherapy effective treatment for liver metastases? No! Important advances in oncology, 1992 Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Forecasting; Humans; Infusio	1992
Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. Journal of the National Cancer Institute, 1991, Mar-20, Volume: 83, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Female; Floxu	1991
[Regional chemotherapy of liver metastases]. Deutsche medizinische Wochenschrift (1946), 1991, Apr-12, Volume: 116, Issue:15 Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Humans; Infusions, Intra-Arterial; Liver N	1991
Two consecutive clinical trials on cisplatin (CDDP), hepatic arterial infusion (HAI), and i.v. 5-fluorouracil (5-FU) chemotherapy for unresectable colorectal liver metastases: an alternative to FUdR-based regimens? Journal of surgical oncology. Supplement, 1991, Volume: 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Floxuridine;	1991
Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. International journal of radiation oncology, biology, physics, 1991, Volume: 20, Issue:3 Topics: Adenoma, Bile Duct; Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Female; Floxuridine; Humans	1991
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Archives of surgery (Chicago, Ill. : 1960), 1990, Volume: 125, Issue:8 Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusion Pump	1990
[Requirements for the randomized trial of i.a. vs. i.v. administration to reveal the impact of hepatic arterial infusion on survival in the treatment of liver metastases]. Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:8 Pt 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Floxuri	1990
Cancer chronotherapy: a drug delivery challenge. Progress in clinical and biological research, 1990, Volume: 341A Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug	1990
A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality	1990
Prognostic factors in liver metastases after transcatheter arterial embolization or arterial infusion. Acta radiologica (Stockholm, Sweden : 1987), 1990, Volume: 31, Issue:3 Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Doxorubicin; Embolization, Therapeutic;	1990
[Is there a primary indication for regional therapy of liver metastases of gastrointestinal tumors?]. Zeitschrift fur Gastroenterologie. Verhandlungsband, 1989, Volume: 24 Topics: Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hu	1989
Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial. Cancer, 1989, Jul-15, Volume: 64, Issue:2 Topics: Adenocarcinoma; Carcinoembryonic Antigen; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fl	1989
Value of in vivo tissue testing in predicting the clinical response to regional perfusion chemotherapy in colorectal cancer patients with liver metastases. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1989, Volume: 165, Issue:7 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorect	1989
[Regional chemotherapy of liver metastases in colorectal carcinoma. Intra-arterial vs intravenous plus intra-arterial therapy]. Deutsche medizinische Wochenschrift (1946), 1989, Sep-29, Volume: 114, Issue:39 Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Evaluation Studies as Topic; Female; F	1989
[Current results and prospects of intra-arterial chemotherapy in hepatic metastases of carcinoma of the colorectum]. La Clinica terapeutica, 1989, Sep-30, Volume: 130, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Flox	1989
A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:11 Topics: Adult; Aged; Colorectal Neoplasms; Drug Implants; Floxuridine; Hepatic Artery; Humans; Infusions, In	1989
Prevention of extrahepatic disease during intraarterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study. Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:12 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju	1989
[European topic: liver surgery II--regional chemotherapy]. Langenbecks Archiv fur Chirurgie. Supplement II, Verhandlungen der Deutschen Gesellschaft fur Chirurgie. Deutsche Gesellschaft fur Chirurgie. Kongress, 1989 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flo	1989
[Clinical trial of 5'-DFUR against various malignant tumors]. Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:12 Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug Adm	1985
[Clinical trial of 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced cancer patients]. Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:12 Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedul	1985
Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. Cancer, 1986, Feb-01, Volume: 57, Issue:3 Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Catheterization; Floxuridine; Hepatic Artery; Hum	1986
Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer, 1986, Feb-01, Volume: 57, Issue:3 Topics: Clinical Trials as Topic; Colonic Neoplasms; Floxuridine; Hepatectomy; Hepatic Artery; Humans; Infus	1986
Treatment of colorectal hepatic metastases by intrahepatic chemotherapy alone or as an adjuvant to complete or partial removal of metastatic disease. Annals of surgery, 1986, Volume: 203, Issue:4 Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Embolization, T	1986
[Regional chemotherapy of liver metastases of colorectal carcinoma using implanted gas pressure pumps. Results of a prospective phase II study]. Deutsche medizinische Wochenschrift (1946), 1986, Apr-25, Volume: 111, Issue:17 Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Female; Floxuridine; Hepatic Artery; Human	1986
Systemic infusional chemotherapy for liver metastasis: an improved schedule for 5-fluorouracil. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1986, Volume: 100 Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Floxuridine; Fluorouracil	1986
Preliminary results of a randomized study of intrahepatic infusion versus systemic infusion of 5-fluoro-2'-deoxyuridine for metastatic colorectal carcinoma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1986, Volume: 100 Topics: Clinical Trials as Topic; Colonic Neoplasms; Female; Floxuridine; Hepatic Artery; Humans; Infusions,	1986
Gastroduodenal mucosal injury during hepatic arterial infusion of chemotherapeutic agents. Lack of cytoprotection by prostaglandin E1 analogue. Gastroenterology, 1987, Volume: 92, Issue:3 Topics: Alprostadil; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Double-Blind	1987
Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Annals of internal medicine, 1987, Volume: 107, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Colonic Neoplasms; Female; Floxuridine; Hepat	1987
Regional infusion for colorectal hepatic metastases. A randomized trial comparing the hepatic artery with the portal vein. Archives of surgery (Chicago, Ill. : 1960), 1987, Volume: 122, Issue:11 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Female; Fl	1987
A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Annals of surgery, 1987, Volume: 206, Issue:6 Topics: Adult; Aged; Colonic Neoplasms; Female; Floxuridine; Humans; Infusions, Intra-Arterial; Infusions, I	1987
Regional infusion of fluoropyrimidines for hepatic metastases of colorectal cancer. Pharmaceutisch weekblad. Scientific edition, 1988, Apr-22, Volume: 10, Issue:2 Topics: Clinical Trials as Topic; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infu	1988
Hepatic infusional chemotherapy in metastatic colorectal carcinoma and hepatoma. The Journal of the Arkansas Medical Society, 1985, Volume: 82, Issue:7 Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colonic Neoplasms; Female; Floxuri	1985
Clinical trial of doxifluridine in the treatment of primary hepatocellular carcinoma. Cancer treatment reports, 1986, Volume: 70, Issue:11 Topics: Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Female; Floxuridine; Humans; Liver Neopla	1986
Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:1 Topics: Aged; Bile Ducts; Cholangiography; Colonic Neoplasms; Female; Floxuridine; Hepatic Artery; Humans; I	1985

floxuridine and Cancer of Liver